Nusinersen (English Wikipedia)

"Spinraza EPAR". European Medicines Agency. 2 April 2012. Retrieved 29 June 2024.
"Spinraza (nusinersen)". European Medicines Agency. Archived from the original on 28 October 2017. Retrieved 27 October 2017.

fiercepharma.com

"Biogen's Spinraza, Fosun Kite's Yescarta and a controversial Alzheimer's drug: All you need to know about China's new state coverage". FiercePharma. 3 December 2021. Retrieved 27 January 2022.

genengnews.com

"Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results", Genetic Engineering News, 1 August 2016

irishtimes.com

"Drugmaker urges HSE to revisit pricing of muscle-wasting disease treatment". Irish Times. 25 February 2019. Retrieved 27 February 2019.

musculardystrophyuk.org

"Biogen statement on Expanded Access Programme". Muscular Dystrophy UK. 2 December 2018. Archived from the original on 28 February 2019. Retrieved 27 February 2019.

newswire.ca

"Biogen's SPINRAZA™ (nusinersen) Receives Notice of Compliance from Health Canada for the Treatment of 5q Spinal Muscular Atrophy (SMA)". Cision. 4 July 2017. Archived from the original on 4 December 2017. Retrieved 13 October 2017.

nice.org.uk

"NICE recommends first ever treatment for children with rare muscle-wasting condition". National Institute of Health and Care Excellence. 15 May 2019. Archived from the original on 28 May 2019. Retrieved 28 May 2019.
Nusinersen for treating spinal muscular atrophy. NICE Technology appraisal guidance [TA588] 2019

nih.gov

pubmed.ncbi.nlm.nih.gov

Paton D (2017). "Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy". Drugs of Today. 53 (6). Clarivate Analytics (US): 327–337. doi:10.1358/dot.2017.53.6.2652413. ISSN 1699-3993. PMID 28799578.
Ottesen EW (January 2017). "ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy". Translational Neuroscience. 8 (1): 1–6. doi:10.1515/tnsci-2017-0001. PMC 5382937. PMID 28400976.
Zanetta C, Nizzardo M, Simone C, Monguzzi E, Bresolin N, Comi GP, et al. (January 2014). "Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials". Clinical Therapeutics. 36 (1): 128–40. doi:10.1016/j.clinthera.2013.11.006. PMID 24360800.
Pao PW, Wee KB, Yee WC, Pramono ZA, Dwipramono ZA (April 2014). "Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene". Molecular Therapy. 22 (4): 854–61. doi:10.1038/mt.2013.276. PMC 3982506. PMID 24317636. The sequence of nusinersen (UCACUUUCAUAAUGCUGG) is listed as N1-Hua in Table I.
Garber K (October 2016). "Big win possible for Ionis/Biogen antisense drug in muscular atrophy". Nature Biotechnology. 34 (10): 1002–1003. doi:10.1038/nbt1016-1002. PMID 27727217. S2CID 37479367.
Singh NN, Howell MD, Androphy EJ, Singh RN (2019). "How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy". Gene Therapy. 24 (9): 520–526. doi:10.1038/gt.2017.34. PMC 5623086. PMID 28485722.

ncbi.nlm.nih.gov

Ottesen EW (January 2017). "ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy". Translational Neuroscience. 8 (1): 1–6. doi:10.1515/tnsci-2017-0001. PMC 5382937. PMID 28400976.
Pao PW, Wee KB, Yee WC, Pramono ZA, Dwipramono ZA (April 2014). "Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene". Molecular Therapy. 22 (4): 854–61. doi:10.1038/mt.2013.276. PMC 3982506. PMID 24317636. The sequence of nusinersen (UCACUUUCAUAAUGCUGG) is listed as N1-Hua in Table I.
Singh NN, Howell MD, Androphy EJ, Singh RN (2019). "How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy". Gene Therapy. 24 (9): 520–526. doi:10.1038/gt.2017.34. PMC 5623086. PMID 28485722.

dailymed.nlm.nih.gov

"Spinraza- nusinersen injection, solution". DailyMed. 30 June 2020. Retrieved 3 November 2020.

ninds.nih.gov

"Nusinersen (Spinraza®) – Spinal Muscular Atrophy (SMA) | National Institute of Neurological Disorders and Stroke". www.ninds.nih.gov. Retrieved 3 June 2024.

nrk.no

Omland E (11 April 2023). "Beslutningsforum seier ja til Spinraza for muskelsjuke i ekstramøte". NRK (in Norwegian Nynorsk). Retrieved 14 April 2023.

nytimes.com

Thomas K (30 December 2016). "Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval". New York Times.{{cite news}}: CS1 maint: overridden setting (link)

reuters.com

"Biogen's pricey muscle drug Spinraza too costly for Britain". Reuters. 13 August 2018. Retrieved 28 May 2019.

sciencemag.org

Wadman M (23 December 2016). "Updated: FDA approves drug that rescues babies with fatal neurodegenerative disease". Science. doi:10.1126/science.aal0476.{{cite journal}}: CS1 maint: overridden setting (link)

semanticscholar.org

api.semanticscholar.org

"New warning of nusinersen-related communicating hydrocephalus". Reactions Weekly. 1714 (1): 3. 1 August 2018. doi:10.1007/s40278-018-50183-2. ISSN 1179-2051. S2CID 195086499.
Garber K (October 2016). "Big win possible for Ionis/Biogen antisense drug in muscular atrophy". Nature Biotechnology. 34 (10): 1002–1003. doi:10.1038/nbt1016-1002. PMID 27727217. S2CID 37479367.

sma-schweiz.ch

"Spinraza – Zulassung nun auch in der Schweiz" (in Swiss High German). SMA Schweiz. 30 September 2017.

smanewstoday.com

"Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU". BioNews Services, LLC. November 2016. Retrieved 15 November 2016.

sps.nhs.uk

"Nusinersen". UK Specialist Pharmacy Service. 28 January 2016. Archived from the original on 13 April 2019. Retrieved 31 December 2016.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.

the-scientist.com

Offord C (1 December 2016). "Oligonucleotide Therapeutics Near Approval". The Scientist.{{cite news}}: CS1 maint: overridden setting (link)

thepharmaletter.com

"Biogen to launch Spinraza in Japan soon". 10 July 2017.
"China's 2021 NDRL listing sees price cuts of up to 95%". www.thepharmaletter.com. Retrieved 27 January 2022.

translate.google.com

Dette er uforståelig og utrolig urettferdig This is incomprehensible and incredibly unfair (google translate)

treatsma.uk

"Spinraza access by country". TreatSMA. 18 October 2018. Retrieved 28 May 2019.

web.archive.org

"Nusinersen". UK Specialist Pharmacy Service. 28 January 2016. Archived from the original on 13 April 2019. Retrieved 31 December 2016.
Tarr P (24 December 2016). "CSHL FDA approval of life-saving SMA drug is hailed by its researcher-inventor at CSHL". Cold Spring Harbor Laboratory. Archived from the original on 1 January 2017. Retrieved 1 January 2017.{{cite news}}: CS1 maint: overridden setting (link)
"Therapeutic Approaches". www.curesma.org. Cure SMA. Archived from the original on 1 January 2017. Retrieved 1 January 2017.
"Press release: Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy | Biogen Media". Biogen. 1 August 2016. Archived from the original on 10 August 2017. Retrieved 1 January 2017.
"Spinraza (nusinersen)". European Medicines Agency. Archived from the original on 28 October 2017. Retrieved 27 October 2017.
"Biogen's SPINRAZA™ (nusinersen) Receives Notice of Compliance from Health Canada for the Treatment of 5q Spinal Muscular Atrophy (SMA)". Cision. 4 July 2017. Archived from the original on 4 December 2017. Retrieved 13 October 2017.
"Biogen statement on Expanded Access Programme". Muscular Dystrophy UK. 2 December 2018. Archived from the original on 28 February 2019. Retrieved 27 February 2019.
"NICE recommends first ever treatment for children with rare muscle-wasting condition". National Institute of Health and Care Excellence. 15 May 2019. Archived from the original on 28 May 2019. Retrieved 28 May 2019.

who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Organization. pp. 413–414. Retrieved 13 March 2017.

worldcat.org

search.worldcat.org

Paton D (2017). "Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy". Drugs of Today. 53 (6). Clarivate Analytics (US): 327–337. doi:10.1358/dot.2017.53.6.2652413. ISSN 1699-3993. PMID 28799578.
"New warning of nusinersen-related communicating hydrocephalus". Reactions Weekly. 1714 (1): 3. 1 August 2018. doi:10.1007/s40278-018-50183-2. ISSN 1179-2051. S2CID 195086499.
Grant C (27 December 2016). "Surprise Drug Approval Is Holiday Gift for Biogen". Wall Street Journal. ISSN 0099-9660. Retrieved 27 December 2016.{{cite web}}: CS1 maint: overridden setting (link)

wsj.com

Grant C (27 December 2016). "Surprise Drug Approval Is Holiday Gift for Biogen". Wall Street Journal. ISSN 0099-9660. Retrieved 27 December 2016.{{cite web}}: CS1 maint: overridden setting (link)